Global Hyperparathyroidism Market

Global Hyperparathyroidism Market Size Insights Forecasts to 2035

• The Global Hyperparathyroidism Market Size Was Estimated at USD 387.33 Million in 2024
• The Market Size is Expected to Grow at a CAGR of around 5.48 % from 2025 to 2035
• The Worldwide Hyperparathyroidism Market Size is Expected to Reach USD 696.77 Million by 2035
• North America is expected to grow the fastest during the forecast period.

According to a research report published by Decisions Advisors and Consulting, the Global Hyperparathyroidism Market Size was worth around USD 387.33 Million in 2024 and is predicted to grow to around USD 696.77 Million by 2035 with a Compound Annual Growth Rate (CAGR) of 5.48 % from 2025 to 2035. This growth pattern is supported by a number of key factors, such as the rising incidence of hyperparathyroidism, the development of treatment approaches, and growing awareness about the disease. The market is driven by a growing demand for effective treatment approaches, owing to a combination of demographic trends and improved diagnostic capabilities.

 

Market Overview

The hyperparathyroidism market includes the healthcare industry segment that is involved in the treatment and management of hyperparathyroidism, a condition that is marked by the overproduction of parathyroid hormone (PTH). The market is involved in the treatment of hyperparathyroidism through calcimimetics, vitamin D analogues, and bisphosphonates, which are pharmacologic therapies, as well as parathyroidectomy, which is a surgical treatment that is still the gold standard for the treatment of primary hyperparathyroidism. Hyperparathyroidism is a health disorder that occurs due to the overproduction of parathyroid hormone (PTH) by the parathyroid glands, which are four small glands in the neck region. This health disorder is primarily associated with the imbalance of calcium in the body. Blood tests, along with kidney function tests, to determine the levels of calcium, phosphorus, and parathyroid hormone in the body. The healthcare provider may further perform a nuclear medicine scan, which involves the injection of a radioactive tracer into the overactive parathyroid glands to determine the abnormal growth of tissues in the body. Additionally, a dual-energy X-ray absorptiometry scan is recommended to determine the effects of high calcium levels on the bones.

 

According to the World Health Organisation (WHO), the prevalence of CKD is estimated to be 13.4% among the global adult population, thereby adding to the prevalence of secondary hyperparathyroidism. Also, according to a study published in the Journal of Clinical Endocrinology & Metabolism, early diagnosis of hyperparathyroidism can lead to improved patient outcomes, thereby increasing treatment rates and market growth.

 

Pathalys Pharma has raised $105 million in an oversubscribed Series B financing to advance its lead drug candidate, upacicalcet, a Japan-approved calcimimetic for secondary hyperparathyroidism (SHPT) in chronic kidney disease patients on dialysis, toward FDA submission and commercialisation in the U.S.

 

Report Coverage

This research report categorises the hyperparathyroidism market based on various segments and regions, forecasts revenue growth, and analyzes trends in each submarket. The report analyses the key growth drivers, opportunities, and challenges influencing the hyperparathyroidism market. Recent market developments and competitive strategies, such as expansion, product launch, development, partnership, merger, and acquisition, have been included to draw the competitive landscape in the market. The report strategically identifies and profiles the key market players and analyzes their core competencies in each sub-segment of the hyperparathyroidism market.     

 

Driving Factors  

The hyperparathyroidism market is on the verge of growth due to the increasing incidence of comorbidities with the ageing population, and the growing awareness among healthcare professionals and patients is further aiding in the early diagnosis and treatment of the condition. Research indicates that early diagnosis has led to a substantial increase in the treatment of hyperparathyroidism, and the advancements in minimally invasive surgical procedures and the development of new pharmacological therapies, such as calcimimetics and vitamin D analogues, have revolutionised the treatment of hyperparathyroidism, with parathyroidectomy being the gold standard. Newer therapies such as cinacalcet are promising in the management of secondary hyperparathyroidism in patients with CKD, further propelling the growth of the hyperparathyroidism market. The strong innovation in the treatment of hyperparathyroidism is evident from the ongoing clinical trials for new calcimimetics and parathyroid hormone analogues.

 

Restraining Factors  

The hyperparathyroidism market, despite its growth potential, is challenged by supply chain bottlenecks and raw material shortages, further exacerbated by the disruptions caused by pandemics, which slowed the production and distribution of drugs. This has resulted in shortages of essential drugs and has further impeded the accessibility of patients to treatment, while the varying costs of raw materials have further derailed growth and the regulatory requirements imposed by bodies.

 

Market Segmentation    

The hyperparathyroidism market share is classified into type, and product.     

 

• The secondary hyperparathyroidism segment accounted for the largest market share in 2024 and is expected to grow at a significant CAGR during the forecast period.        

Based on the type, the hyperparathyroidism market is divided into primary hyperparathyroidism, secondary hyperparathyroidism, and tertiary hyperparathyroidism. Among these, the secondary hyperparathyroidism segment accounted for the largest market share in 2024 and is expected to grow at a significant CAGR during the forecast period. Secondary hyperparathyroidism is strongly associated with chronic kidney disease (CKD), which continues to show a high and rising global prevalence, creating significant demand for treatment. The secondary hyperparathyroidism typically requires long-term drug therapy with agents like calcimimetics and vitamin D analogues. This sustained treatment need results in higher recurring costs, thereby driving greater revenue contribution to the overall hyperparathyroidism treatment market.

• The parathyroid hormone segment accounted for the highest market revenue in 2024 and is anticipated to grow at a significant CAGR during the forecast period.      

Based on the product, the hyperparathyroidism market is divided into parathyroid hormone, vitamin D analogues, and calcium supplements. Among these, the parathyroid hormone segment accounted for the highest market revenue in 2024 and is anticipated to grow at a significant CAGR during the forecast period. This is because the parathyroid hormone provides a specific mechanism of action for the treatment of hyperparathyroidism that is not provided by other forms of products. Hyperparathyroidism results from high parathyroid hormone levels in the body. The parathyroid hormone plays a critical role in maintaining the levels of calcium and phosphate in the body. High parathyroid hormone levels can cause bone loss, kidney stones, and other disorders in the body. Reducing the parathyroid hormone levels is essential for the management of hyperparathyroidism.

 

Regional Segment Analysis of the Hyperparathyroidism Market

• North America (U.S., Canada, Mexico) 
• Europe (Germany, France, U.K., Italy, Spain, Rest of Europe)
• Asia-Pacific (China, Japan, India, Rest of APAC)
• South America (Brazil and the Rest of South America) 
• The Middle East and Africa (UAE, South Africa, Rest of MEA)

 

Asia Pacific is anticipated to hold the largest share of the hyperparathyroidism market over the predicted timeframe.     

Asia Pacific is anticipated to hold the largest share of the hyperparathyroidism market over the predicted timeframe. The factors driving the market growth are the increasing prevalence of hyperparathyroidism, growing healthcare expenditure, and developing healthcare infrastructure. The number of cases in countries such as China and India is increasing, thereby driving the demand for treatment options. Initiatives by the government, such as the National Health Mission in India, which focuses on enhancing the quality of healthcare, are expected to drive the market growth. The Indian government has allocated INR 2.5 trillion (USD 30 billion) in the 2023-2024 budget for healthcare projects.

 

In August 2023, Kyowa Kirin received approval in Japan for ORKEDIA® Tablets 4mg (generic name: evocalcet), an oral calcimimetic agent. It is used to suppress parathyroid hormone (PTH) secretion. The approval was granted by Japan’s Ministry of Health, Labour and Welfare (MHLW).

 

North America is expected to grow at a rapid CAGR in the Hyperparathyroidism market during the forecast period. This can be attributed to the high incidence of hyperparathyroidism, the advanced healthcare infrastructure, and the investments in research and development. The United States leads the market in North America, with an advanced healthcare infrastructure that promotes early diagnosis and treatment. Government support, such as the National Institute of Health's (NIH) support for research into endocrine diseases, further fuels the growth of the market. The NIH allocated USD 1.2 billion to research into CKD and associated diseases in 2023, indicating the efforts being made to combat the increasing incidence of hyperparathyroidism.

 

In August 2024, the U.S. FDA approved YORVIPATH® (palopegteriparatide), developed by Ascendis Pharma, as the first and only treatment specifically indicated for adults with hypoparathyroidism. This marks a major milestone in endocrine care, offering a targeted therapy beyond conventional calcium and vitamin D supplementation.

 

Competitive Analysis:   

The report offers the appropriate analysis of the key organizations/companies involved within the hyperparathyroidism market, along with a comparative evaluation primarily based on their product offering, business overviews, geographic presence, enterprise strategies, segment market share, and SWOT analysis. The report also provides an elaborative analysis focusing on the current news and developments of the companies, which includes product development, innovations, joint ventures, partnerships, mergers & acquisitions, strategic alliances, and others. This allows for the evaluation of the overall competition within the market.  

 

List of Key Companies

• AbbVie Inc. (Zemplar)
• Amgen Inc. (Sensipar/Mimpara, Parsabiv)
• Astellas Pharma Inc. (SHPT therapies)
• Fresenius Medical Care AG & Co. KGaA (dialysis SHPT)
• Kyowa Kirin Co., Ltd. (calcimimetics)
• Novartis AG (generics/pipeline)
• OPKO Health, Inc. (Rayaldee)
• Pathalys Pharma (upacicalcet Phase III)
• Roche Holding AG (endocrine portfolio)
• Sanofi S.A. (Hectorol)
• Shire Pharmaceuticals (legacy SHPT)
• Takeda Pharmaceutical Company Limited (cinacalcet partners)
• Teva Pharmaceutical Industries Ltd. (generics)
• Vifor Pharma AG (Rayaldee partners)
• Others  

 

Key Target Audience

• Market Players
• Investors
• End-users
• Government Authorities 
• Consulting and Research Firm
• Venture capitalists
• Value-Added Resellers (VARs) 

 

Recent Development

 

• In July 2025, the Norman Parathyroid Centre launched the first-ever Hyperparathyroidism Awareness Day, alongside a national partnership with Any Lab Test Now to expand access to diagnostic testing across the U.S. This initiative aims to improve early detection of hyperparathyroidism, a common but underdiagnosed endocrine disorder, particularly among women over 50.

 

Market Segment  

This study forecasts revenue at global, regional, and country levels from 2020 to 2035. Decisions Advisors has segmented the hyperparathyroidism market based on the below-mentioned segments: 

  

Global Hyperparathyroidism Market, By Type

• Primary Hyperparathyroidism
• Secondary Hyperparathyroidism
• Tertiary Hyperparathyroidism

 

Global Hyperparathyroidism Market, By Product

• Parathyroid Hormone
• Vitamin D Analogue
• Calcium Supplements

 

Global Hyperparathyroidism Market, By Regional Analysis

• North America
  • US
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Russia
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Rest of Asia Pacific
• South America
  • Brazil
  • Argentina
  • Rest of South America
• Middle East & Africa
  • UAE
  • Saudi Arabia
  • Qatar
  • South Africa
  • Rest of the Middle East & Africa

 

Frequently Asked Questions (FAQ)

 

1. What is the current size of the global hyperparathyroidism market?

The market was valued at USD 387.33 million in 2024.

 

2. What is the projected market size by 2035?

It is expected to reach USD 696.77 million by 2035.

 

3. What is the CAGR for the market from 2025 to 2035?

The market is forecasted to grow at a CAGR of 5.48%.

 

4. Which type of hyperparathyroidism holds the largest market share?

Secondary hyperparathyroidism accounted for the largest share in 2024, driven by its link to chronic kidney disease.

 

5. Which product segment leads the market by revenue?

Parathyroid hormone generated the highest revenue in 2024 and is expected to grow significantly.

 

6. Which region is expected to grow the fastest?

North America is projected to grow at the fastest CAGR, due to advanced healthcare and high incidence rates.

 

7. What are the main drivers of market growth?

Rising incidence with ageing populations, better diagnostics, and new treatments like calcimimetics fuel expansion.

 

8. Who are some key players in the market?

Major companies include Amgen Inc., Kyowa Kirin, AbbVie Inc., and Pathalys Pharma.